MEDITECH RESEARCH LIMITED 2002-06-06 ASX-SIGNAL-G
HOMEX - Perth
+++++++++++++++++++++++++
Continued pre-clinical testing of the Meditech Research Limited
anti-cancer drug HyDOX(TM), has demonstrated that it substantially
reduces heart damage that is often associated with doxorubicin
chemotherapy. Breast and many other cancer patients are commonly
treated with doxorubicin but prolonged treatment results In
irreversible heart damage which reduces the amount of treatment a
patient can tolerate with this efficacious, but toxic chemotherapy.
Meditech Research has developed HyDOX(TM) a doxorubicin-hyaluronan
combination using its patented HyACT(TM) platform technology. Prof
Richard Fox of the Centre for Development of Cancer Therapeutics said
"Earlier pre-clinical studies comparing HyDOX(TM) with doxorubicin
alone clearly demonstrated that the Meditech product has superior
anti-tumour capabilities so we are particularly encouraged that the
reduction in cardiotoxicity seen in pre-clinical testing will be
confirmed in human clinical trials. This could enable cancer patients
to receive a treatment protocol with HyDOX(TM) that improves tumour
response, substantially reduces associated toxicity, and offers the
prospect of prolonged patient survival as well."
Researchers at Monash University (Melbourne), University of
Queensland and University of Western Australia utilised an animal
model which has been developed by the USA Food and Drug
Administration (FDA) as the best method of testing cardiotoxicity of
drugs. Findings from these pre-clinical studies demonstrated a 3-fold
reduction in heart damage using Meditech's HyDOX(TM).
Several companies sell products designed specifically to mitigate
heart damage related to the administration of anti-cancer products
such as doxorubicin. None of these offer any enhanced anti-tumor
activity. The annual market for the two most widely used of these
products is approximately US$120million(1). In contrast, HyDOX(TM)
would offer an alternative which is not only far less costly to
produce, but would provide anti-tumor effects as well as reduced
cardiotoxicity.
Meditech Research has recently completed the Phase 1 human trialling
of HyDOX(TM) and is currently in the design phase for Phase 2 human
testing. This new finding that HyDOX(TM) reduces heart damage will
assist Meditech in the design of an even more focused and effective
Phase 2 study.
FOR FURTHER INFORMATION, CONTACT:
Meditach: http://www.mrl.com.au
Professor Richard Fox: (03) 0342 7695
Dr Tracey Brown, (03) 9905 3760
- Forums
- ASX - By Stock
- SRT
- New heart drug report
New heart drug report, page-5
Featured News
Add SRT (ASX) to my watchlist
(20min delay)
|
|||||
Last
18.0¢ |
Change
0.020(12.5%) |
Mkt cap ! $30.49M |
Open | High | Low | Value | Volume |
18.5¢ | 18.5¢ | 18.0¢ | $9.305K | 51.64K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 50000 | 18.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
18.5¢ | 3603 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 5000 | 0.160 |
1 | 5000 | 0.150 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.185 | 3603 | 1 |
0.190 | 200000 | 1 |
0.200 | 4000 | 1 |
0.250 | 25000 | 1 |
0.000 | 0 | 0 |
Last trade - 13.50pm 28/03/2024 (20 minute delay) ? |
Featured News
SRT (ASX) Chart |
The Watchlist
BGD
BARTON GOLD HOLDINGS LIMITED
Alex Scanlon, Managing Director & CEO
Alex Scanlon
Managing Director & CEO
SPONSORED BY The Market Online